bococizumab development code drug development pfizer targeting reduce ldl pfizer withdrew drug development november determining likely provide value patients physicians bococizumab monoclonal antibody inhibits protein interferes removal ldl ldl levels major risk factor cardiovascular phase study statin patients presented american college monthly bimonthly injections resulted significantly reduced ldlc week phase spire trials dosefinding studies found bococizumab significantly reduce ldl cholesterol levels commonly associated antidrug antibodies development antidrug antibodies bococizumab led attenuation ldl lowering weeks wide variation relative reduction cholesterol levels additionally observed among developing antidrug antibodies assessing data pfizer abandoned development bococizumab monoclonal article stub help wikipedia expanding drug article relating cardiovascular system stub help wikipedia expanding httpsenwikipediaorgwikibococizumab